<DOC>
	<DOCNO>NCT02235545</DOCNO>
	<brief_summary>The purpose post approval study characterize chronic performance SJM Optisure family HV lead patient .</brief_summary>
	<brief_title>Optisure Lead Post Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<criteria>Eligible patient meet following : 1 . Have approve indication , per ACC/AHA/HRS/ESC guideline , implantation ICD CRTD system treatment heart failure lifethreatening ventricular tachyarrhythmia ( ) . 2 . Have implant St. Jude Medical Optisure lead last 30 day schedule Optisure lead implant . 3 . Have ability provide inform consent study participation willing able comply prescribe followup test schedule evaluation . 4 . Are 18 year , legal age give inform consent specific state national law . Patients exclude meet following : 1 . Enrolled intend participate clinical drug and/or device study , could confound result trial determine SJM , course clinical study . 2 . Have life expectancy le 5 year due condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HV Lead</keyword>
	<keyword>ICD</keyword>
	<keyword>CRT-D System</keyword>
	<keyword>Treatment Heart Failure</keyword>
	<keyword>Treamtent life-threatening ventricular tachyarrhythmia</keyword>
	<keyword>Optisure</keyword>
</DOC>